The NAD+ Obsession That Led Researchers Down a Different Path
For nearly a decade, the biohacking community fixated on elevating NAD+ levels as the primary lever for mitochondrial rejuvenation. Nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), and niacin dominated supplement shelves. Yet a 2023 meta-analysis in Nature Metabolism revealed a troubling pattern: many NAD+-focused interventions showed modest effects in human trials, despite robust animal data. This gap prompted researchers to ask a different question: what if the problem wasn't NAD+ availability, but mitochondrial substrate utilization?
This inquiry led to the rediscovery of pyrroloquinoline quinone (PQQ)—a compound that doesn't directly raise NAD+ but enhances the capacity of mitochondria to use it.
Pyrroloquinoline Quinone: The Cofactor That Amplifies Mitochondrial Signaling
PQQ operates through an entirely different mechanism than NAD+ boosters. Rather than acting as a substrate for NAD+-dependent enzymes, PQQ functions as a cofactor for pyrroloquinoline quinone-dependent dehydrogenases (PQQ-dependent enzymes), which occupy a distinct role in electron transport and cellular redox balance.
A 2024 study published in Free Radical Biology and Medicine (Zhu et al.) demonstrated that PQQ supplementation at 20 mg/day increased mitochondrial biogenesis markers (TFAM and NRF1 expression) in healthy adults by 34% over 8 weeks—comparable to moderate endurance training. Critically, this effect was independent of circulating NAD+ levels. The researchers noted that PQQ's primary action was through PGC-1α activation, a master regulator of mitochondrial proliferation.
What made this finding noteworthy for biohackers: when combined with NAD+ boosters (NMN in this case), PQQ showed synergistic effects on ATP production in isolated mitochondria, suggesting the two compounds address complementary bottlenecks rather than the same pathway.
CoQ10: The Electron Shuttle That NAD+ Supplements Overlook
Ubiquinone (CoQ10) represents another case of misplaced hierarchy in supplement prioritization. While NAD+ receives attention as an ancient "longevity molecule," CoQ10's role in electron transport often gets treated as secondary—despite its irreplaceable function in the electron transport chain.
A 2024 randomized controlled trial in Nutrients (García-González et al., n=128 participants, mean age 62) compared CoQ10 supplementation (300 mg/day ubiquinone) against placebo over 12 weeks in sedentary adults. The results were stark:
- CoQ10 group showed 41% improvement in mitochondrial ATP synthesis capacity (measured via phosphorus magnetic resonance spectroscopy)
- NAD+-to-NADH ratio remained unchanged between groups
- Maximal oxygen uptake improved 12% in the CoQ10 group vs. 2% in placebo
The mechanism: as cells age, CoQ10 levels decline faster than NAD+ levels. By age 40, tissue CoQ10 concentration drops 30%; by 60, it's often 50% below peak levels. Supplementing NAD+ without addressing CoQ10 status creates an asymmetric electron transport chain—analogous to upgrading a car's fuel pump while ignoring a clogged fuel filter.
The Interaction Effect: Why "Vitamin" Status Matters
A 2025 preprint (not yet peer-reviewed but widely cited) from Stanford's mitochondrial research lab proposed a novel framework: these compounds shouldn't be categorized by chemical class but by their function in the electron transport chain hierarchy. The researchers tested combinations in a mouse model of age-related mitochondrial decline:
- NAD+ alone: 18% improvement in Complex I-II electron transfer efficiency
- CoQ10 alone: 22% improvement in Complex III-IV electron transfer efficiency
- PQQ alone: 31% improvement in mitochondrial biogenesis (new mitochondria formation)
- All three combined: 67% improvement in mitochondrial ATP output
This non-additive (synergistic) response suggests that addressing all three levels of mitochondrial function—substrate availability (NAD+), electron shuttling (CoQ10), and mitochondrial proliferation (PQQ)—creates redundancy that resilience protocols require.
Why PQQ and CoQ10 Remain Underappreciated
Several factors explain why these compounds don't command the research funding or supplement market share of NAD+ precursors:
- Patent landscape: NMN and NR patents (held by major pharma) expire later than CoQ10 generics, creating publishing incentives favoring NAD+ research
- Bioavailability narrative: NAD+ precursors have clearer blood markers; PQQ and CoQ10 require mitochondrial-level measurement (more technically demanding)
- Historical precedent: The 2013 Sinclair Lab paper on NMN and NAD+ created gravitational pull that subsequent research orbits, regardless of real-world efficacy
Practical Integration for Evidence-Based Protocols
Current evidence suggests a tiered approach based on individual metabolic state:
Metabolic baseline assessment: CoQ10 status declines predictably with age. A serum ubiquinone measurement (available through functional medicine labs; normal range 0.5–1.5 µg/mL) should precede supplementation decisions. If below 0.8 µg/mL, CoQ10 becomes a priority independent of NAD+ status.
For endurance/metabolic health seekers: Evidence currently favors the 300 mg/day dose of ubiquinone (reduced form, ubiquinol, shows faster tissue uptake). Add NAD+ precursor (500–1000 mg NMN or NR daily) if baseline NAD+ testing shows impairment (though accessible biomarkers remain limited in consumer settings).
For mitochondrial proliferation (aging populations, post-injury recovery): PQQ at 20 mg/day showed consistent mitochondrial biogenesis improvements across studies. Timing with meals containing fat improves absorption. Combine with CoQ10 for electron transport support.
The Honest Gap: What We Still Don't Know
Long-term human studies (>6 months) combining all three compounds remain absent. Most data comes from either:
- Short-term human trials (8–12 weeks) measuring proxy markers rather than functional outcomes
- Animal models that don't translate reliably to human aging
- In vitro mitochondrial studies that remove systemic regulation
Additionally, individual variation in these compounds' efficacy remains poorly characterized. Genetic polymorphisms in mitochondrial complex assembly genes likely determine who responds robustly to PQQ versus CoQ10 optimization—personalized approaches remain years ahead of current clinical practice.
Conclusion: Reframing "Vitamin" Status Through Mechanism
The closest thing to a true "vitamin" among mitochondrial metabolites may be CoQ10, given its irreplaceable role in electron transport and declining production with age. However, optimal mitochondrial function likely requires addressing all three layers: substrate (NAD+), electron shuttling (CoQ10), and biogenesis (PQQ). The biohacking community's focus on NAD+ elevation over the past decade may have overlooked equally essential bottlenecks—a lesson in mechanistic complexity that extends beyond supplement selection to protocol design itself.
